Prevalence of Hyperapolipoprotein B and Associations with Other Cardiovascular Risk Factors Among Human Immunodeficiency Virus–Infected Patients in Pernambuco,Brazil
Restricted accessResearch articleFirst published online October, 2010
Prevalence of Hyperapolipoprotein B and Associations with Other Cardiovascular Risk Factors Among Human Immunodeficiency Virus–Infected Patients in Pernambuco,Brazil
Hypertriglyceridemia associated with low high-density lipoprotein (HDL) levels and hypercholesterolemia is the most common metabolic disorder among human immunodeficiency virus (HIV)–infected patients using antiretroviral therapy. This atherogenic profile is associated with increased cardiovascular risk among these patients. Apolipoprotein B (apoB) is a better parameter than low-density lipoprotein (LDL) for evaluating lipids and cardiovascular risk among patients with diabetes and metabolic syndrome, but studies of apoB among HIV-infected patients are scarce.
Methods:
A cross-sectional study was conducted to estimate hyperapolipoprotein B (hyperapoB) prevalence and its association with other factors among HIV-infected patients attended in Recife, Pernambuco, Brazil.
Results:
The prevalence of hyperapoB was 32.4% among 256 patients (62.1% male), with 90 mg/dL as the cutoff point. It was associated with prolonged use (>3 years) of antiretroviral therapy [odds ratio (OR), 3.63; 95% confidence interval (CI), 1.24–10.6], hypertriglyceridemia (OR, 2.45; 95% CI, 1.22–4.91), insulin resistance according to homeostasis model assessment of insulin resistance (HOMA-IR) (OR, 2.12; 95% CI, 1.03–4.35), past history of diabetes (OR, 3.58; 95% CI, 1.0–12.7), and hypertension (OR, 1.98; 95% CI, 0.92–4.28). It was not associated with low HDL levels or self-report lipodystrophy. ApoB was higher in patients with metabolic syndrome according to the National Cholesterol Education Program (NCEP) criteria and in those with higher Framingham scores.
Conclusions:
ApoB is a good parameter for evaluating lipid levels in HIV-infected patients with hypertriglyceridemia, among whom LDL measurements may not be appropriate. ApoB might be useful for diagnosing and treating hypertriglyceridemia in this population. The association between hyperapoB and hypertriglyceridemia and diseases relating to insulin resistance among HIV-infected patients suggests that this group of patients presents higher cardiovascular risk.
Get full access to this article
View all access options for this article.
References
1.
GrunfeldC, PangM, DoerrlerW, ShigenagaJK, JensenP, FeingoldKR. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab, 1992; 74:1045–1052.
2.
GrinspoonS, CarrA. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med, 2005; 352:48–62.
3.
CarrA, SamarasK, BurtonS, FreundF, ChisholmDJ, CooperDA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS, 1998; 12:F52–F58.
4.
GazzarusoC, SacchiP, GarzanitiA, FratinoP, BrunoR, FiliceG. Prevalence of metabolic syndrome among HIV patients. Diabetes Care, 2002; 25:1253–1254.
5.
JericóC, KnobelH, MenteroM, Ordoñez-LlanosJ, GullarA, GimenoJL, SabalesP, López-ColomésJL, Pedro-BotetJ. Metabolic syndrome among HIV-infected patients. Diabetes Care, 2005; 28:132–137.
6.
HadiganC, MeigsJB, CorcoranC, RietschelP, PiecuchS, BasgozN, DavisB, SaxP, StanleyT, WilsonPW, D'AgostinoRB, GrinspoonS. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis, 2001; 32:130–139.
7.
CarrA, SamarasK, ThorisdottirA, KaufmannGR, ChisholmDJ, CooperDA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet, 1999; 353:2093–2099.
8.
TsiodorasS, MantzorosC, HammerS, SamoreM. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy. A 5-year cohort study. Arch Intern Med, 2000; 160:2050–2056.
9.
WalliR, HerfortO, MichlGM, DemantT, JägerH, DieterleC, BognerJR, LandgrafR, GoebelFD. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS, 1998; 12:F167–F173.
10.
PilieroPJ. Mechanisms of lipid elevation associated with the treatment of patients with HIV infection[article online]Medscape General Medicine, 2003; 5,2posted 06/04/2003www.medscape.com/viewarticle/456058/. 2008 January 20.
11.
LamarcheB, TchernofA, MoorjaniS, CantiB, DagenaisGR, LupienPJ, DesprésJP. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: Prospective results from the Quebec Cardiovascular Study. Circulation, 1997; 95:69–75.
12.
SnidermanAD, ScantleburyT, CianfioneK. Hypertrigliceridemic hyperapoB: The unappreciated atherogenic dyslipoproteinemia in type 2 diabetes. Ann Inter Med, 2001; 135:447–459.
13.
FriedewaldWT, LevyR, FredricksonDS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18:499–502.
14.
SnidermanAD, MarcovinaSM. Apoliprotein A1 and B. Clin Lab Med, 2006; 26:733–750.
15.
SteinEA, SnidermanA, LaskarzewskiP. Assesment of reaching goal in patients with combined hyperlipidemia: Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B. Am J Cardiol, 2005; 96:36K–43K.
16.
SchmitzM, MichlGM, WalliR, BognerJ, BedynekA, SeidelD, GoebelFD, DemantT. Alterations of apolipoprotein B metabolism in HIV-Infected patients with antiretroviral combination therapy. J Acquir Immune Defic Syndr, 2001; 26:225–235.
17.
PetitJM, DuongM, FlorentinE, DuvillardL, ChavanetP, BrunJM, PortierH, GambertP, VergèsB. Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen: A stable isotope kinetic study. J Lipid Res, 2005; 44:1692–1697.
18.
ReedsDN, MittendorferB, PattersonBW, PowderlyWG, YarashekiKE, KleinS. Alterations in lipid kinetics in men with HIV-dyslipidemia. Am J Physiol Endocrinol Metab, 2003; 285:E490–E497.
19.
ShahmaneshM, DasS, StolinskiM, Shojaee-MoradieF, JacksonNC, JeffersonW, CrambR, NightingaleP, UmplebyM. Antiretroviral treatment reduces very-low-density lipoprotein and intermediate-density lipoprotein apolipoprotein B fractional catabolic rate in human immunodeficiency virus-infected patients with mild dyslipidemia. J Clin Endocrinol Metab, 2005; 90:755–760.
20.
UmplebyAM, DasS, StolinskiM, Shojaee-MoradieF, JacksonNC, JeffersonW, CrabtreeN, NightingaleP, ShahmaneshM. Low density lipoprotein apolipoprotein B metabolism in treatment–naïve HIV patients and patients on antiretroviral therapy. Antivir Ther, 2005; 10:663–670.
21.
CarpentierA, PattersonBW, UffelmanKD, SalitI, LewisGF. Mechanism of highly active anti-retroviral therapy-induced hiperlipidemia in HIV-infected individuals. Atherosclerosis, 2005; 178:165–172.
22.
BrunzellJD. Hypertriglyceridemia. N Engl J Med, 2007; 357:1009–1017.
23.
BeaumontJL, CarlsonLA, CooperGR, FeijarZ, FredricksonDS, StrasserT. Classification of hyperlipidemia and hyperlipoproteinemias. Bull World Health Organ, 1970; 43:891–908.
24.
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care, 1997; 20:1183–1197.
25.
IV Brazilian Guideline on Hypertension. Arq Bras Cardiol, 2004; 82,S4:7–22.
26.
Expert panel on detection evaluation and treatment of high blood cholesterol in adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III)JAMA, 2001; 285:2486–2497.
27.
AlbertiKGM, ZimmetP, ShawJ. Metabolic Syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med, 2006; 23:469–480.
28.
GelonezeB, RepettoEM, GelonezeSR, TambasciaMA, ErmeticeMN. The threshold value for insulin resistance (HOMA-IR) in an admixtured population IR in the Brazilian Metabolic Syndrome Study. Diabetes Res Clin Pract, 2006; 72:219–220.
29.
WilsonPWF, D'AgostinoRB, LevyD, BelangerBS, SilbershatzH, KannelWB. Prediction of coronary heart disease using risk factor categories. Circulation, 1998; 97:1837–1847.
30.
CraigCL, MarshallA, SjostromM, BaumanAE, BoothML, AinsworthBE, PrattM, EkelundU, YngveA, SallisJF, OjaP. International Physical Activity Questionnaire: 12 country reliability and validity. Med Sci Sports Exerc, 2003; 35:1381–1395.
31.
MartelliCMT, TurchiMD, SoutoFDJ, SaezA, AndradeALSS, ZickerF. Anti-Hbc testing for blood donations in areas with intermediate hepatitis B endemicity. Rev Panam Salud Publica, 1999; 6:69–73.
32.
LandisJR, KochGG. The measurement of observer agreement for categorical data. Biometrics, 1977; 33:159–174.
33.
SnidermanAD, LamarcheB, TilleyJ, SeccombeD, FrohlichJ. Hypertrigliceridemic hyperapoB in type 2 diabetes. Diabetes Care, 2002; 25:579–582.
34.
BehrensG, DejamA, SchmidtH, BalksHJ, BrabantG, KornerT, StollM, SchmidtRE. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS, 1999; 13:F63–F70.
35.
AraújoPSR, XimenesRAA, LopesCF, DuarteJY, SilvaMM, CarneiroEM. Antiretroviral treatment for HIV infection/AIDS and the risk of developing hyperglycemia and hyperlipidaemia. Rev Inst Med Trop S Paulo, 2007; 49:73–78.
36.
AlbuquerqueEMV, De FariaEC, OliveiraHCF, MagroDO, CastilhoLN. High frequency of Fredrickson's phenotypes IV and IIb in Brazilians infected by human immunodeficiency virus. BMC Infect Dis, 2005; 5:47.
37.
The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med, 2003; 349:1993–2003.
38.
The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med, 2007; 356:1723–1735.
39.
KimBJ, HwangST, SungKC, KimBS, KangJH, LeeMH, ParkJR. Comparison of the relationships between serum apolipoprotein B and serum lipid distributions. Clin Chem, 2005; 51:2257–2263.
40.
ContoisJH, McNamaraJR, Lammi-KeefeCJ, WilsonPW, MassovT, SchaeferEJ. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: Results from the Framingham Offspring Study. Clin Chem, 1996; 42:489–491.
41.
GrinspoonSK. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med, 2005; 118:23S–28S.
CorsettiJP, ZarebaW, MossAJ, SparksCE. Apolipoprotein B determines risk for recurrent coronary events in postinfarction patients with metabolic syndrome. Atherosclerosis, 2004; 177:367–373.
44.
JiangR, SchulzeMB, LiT, RifaiN, StampferMJ, RimmEB, HuFB. Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes. Diabetes Care, 2004; 27:1991–997.
45.
DenkeMA. Weighing in before the fight. Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measurement of therapy. Circulation, 2005; 112:3368–3370.
46.
LemieuxI, PascotA, CouillardC, LamarcheB, TchernofA, AlmérasN, BergeronJ, GaudetD, TremblayG, Prud'hommeD, NadeauA, DesprésJP. Hypertriglyceridemic waist. A marker of the atherogenic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men?Circulation, 2000; 102:179–184.
47.
St-PierreAC, CantinB, DagenaisGR, DesprésJP, LamarcheB. Apolipoprotein-B, low-density lipoprotein cholesterol, and long-term risk of coronary heart disease in men. Am J Cardiol, 2006; 97:997–1001.
48.
WalldiusG, JungnerI, HolmeI, AastveitAH, KolarW, SteinerE. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): A prospective study. Lancet, 2001; 358:2026–2033.
